Hepatic safety of sintilimab versus pembrolizumab in advanced non-small cell lung cancer: a retrospective observational cohort study - Top-Institutions - MDSpire

Hepatic safety of sintilimab versus pembrolizumab in advanced non-small cell lung cancer: a retrospective observational cohort study

  • By

  • Pan Ma

  • Yumeng Zhou

  • Xin Zhang

  • Quanfeng Zhao

  • Yu Peng

  • Hailong Jiang

  • Linli Xie

  • Yan Liao

  • June 24, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Southwest Hospital
    Southwest Hospital

    Chongqing, China

    Key Differentiators

    • Oncology

  • #3

    First Affiliated Hospital of Army Medical University
    First Affiliated Hospital of Army Medical University

    Chongqing, China

    Key Differentiators

    • Oncology

  • #4

    Johns Hopkins Sidney Kimmel Cancer Center
    Johns Hopkins Sidney Kimmel Cancer Center

    Baltimore, MD

    Key Differentiators

    • Oncology

  • #5

    Shanghai Chest Hospital
    Shanghai Chest Hospital

    Shanghai, China

    Key Differentiators

    • Oncology

Original Source(s)

Hepatic safety of sintilimab versus pembrolizumab in advanced non-small cell lung cancer: a retrospective observational cohort study

  • by Pan Ma, Yumeng Zhou, Xin Zhang, Quanfeng Zhao, Yu Peng, Hailong Jiang, Linli Xie, Yan Liao

  • June 24, 2026

Related Content

The impact of the large B-cell lymphoma tumor microenvironment on efficacy of CD19-directed CAR-T immunotherapy

Gitogenin impedes tumorigenesis in hepatocellular carcinoma via NUAK2/NF-κB axis

Outcomes of malignant orbital tumors: a 22-year Norwegian single-center series